AGN-210669 + bimatoprost

AGN-210669 + bimatoprost is a **combination ophthalmic regimen** under investigation for the treatment of **primary open-angle glaucoma** and **ocular hypertension**. AGN-210669 is an investigational compound (possibly a unique small molecule or analog) evaluated both as monotherapy and in combination with **bimatoprost** (a prostamide/prostaglandin F2α analog that lowers intraocular pressure by increasing uveoscleral outflow). The combination aims to achieve superior intraocular pressure (IOP) reduction compared to either agent alone, potentially benefiting patients inadequately controlled on current therapies[1][3][4].